WA-SPIE
8.2.2024 22:02:36 CET | Business Wire | Press release
SPIE, the international society for optics and photonics, held an impactful and vibrant Photonics West last week at San Francisco’s Moscone Center, with 24,000-plus technical professionals registered from more than 70 countries across the international optics and photonics community. The largest annual photonics conference, which ran from 27 January to 1 February, hosted over 1,500 exhibitors, and featured over 5,000 technical presentations across an interactive and engaging week that included BiOS, LASE, OPTO, Quantum West, the BiOS Expo, the Photonics West exhibition, the Quantum West Expo, and the co-located AR|VR|MR conference and exhibition.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240208158413/en/
SPIE Photonics West 2024 hosted an enthusiastic crowd of optics and photonics professionals at San Francisco's Moscone Center. (Photo: Business Wire)
“Photonics West heralds the beginning of the optics and photonics calendar each year for good reason,” said SPIE CEO Kent Rochford. “The invigorating energy and high levels of enthusiasm throughout the Moscone Center characterized a truly exciting week. AR|VR|MR continues to grow by leaps and bounds, and the addition of a standalone exhibit to the Quantum West program reflects the growing impact of the technology. We were also delighted by the success of our brand-new SPIE Global Business Forum, a packed event that drew top industry executives together for high-level presentations and conversation. Altogether it was a pleasure to be part of the networking, research-sharing, and collaborative discussions among world-leading scientists, engineers, students, and businesspeople and I’m already looking forward to Photonics West 2025.”
As always, the dynamic week showcased the latest innovative technologies and discoveries stemming from a diverse and thriving optics and photonics community, bringing together researchers, innovators, engineers, entrepreneurs, and business leaders from across the globe. Over 100 distinct technical conferences paired perfectly with the four exhibitions held during the week, bringing researchers and companies together to further science, technology, and applications. The week also included a wide range of live product demonstrations on the exhibition floors as well as a job fair.
The inaugural SPIE Global Business Forum was a resounding, sold-out success. With the 16th annual Prism Awards honoring the top new optics and photonics products, and the fast-paced Startup Challenge pitch competition, SPIE Photonics West recognized the best optics and photonics technologies, trends, and entrepreneurial opportunities, while the Quantum West Business Summit featured talks and panels that provided key insights into that expanding commercial ecosystem.
In addition, a program of 56 educational courses offered expert-led technical training and learning, which complemented the dozens of professional development and networking sessions. From Lunch and Learn programming focused on EDI, to networking and social events that provided many opportunities for in-person conversations and possible future collaborations, Photonics West featured a packed calendar of special events.
While the week held myriad opportunities for attendees to learn, network, and share their latest advancements, it was the buzzing exhibitions that best showcased the increasingly vital photonics industry and the importance of in-person meetings.
“The Global Business Forum made it clear that the optics and photonics industry is in the midst of a remarkable era of growth and innovation,” said Stratos Kehayas, PhD, Chief Product & Technology Officer, G&H. “The industry's collective enthusiasm at Photonics West underscores the pivotal role this trade show plays in driving collaboration, fostering innovation, and shaping the future.”
"This has been arguably one of the most productive Photonics Wests we've had in the last five years,” said nLIGHT Vice President and General Manager, Semiconductor Lasers, Matthew Randall. “It’s been very engaging, with lots of people coming through, and we're seeing new things at our booth and at other booths that make this particular show a positive experience. We are definitely seeing way more innovation now than in the last couple of years and that's been incredibly positive not only for nLIGHT, but for the entire photonics industry.”
“The week has been very good,” said MKS Instruments Senior Director of Marketing, Photonics Solutions Division, Vincent M. Issier. “The traffic has been very high and the attendance is incredible this year, and we are very happy with the level of engagement from people here.”
“The week has been great,” said IPG Photonics Director of Product Management, Beam Delivery, UV, Green & Ultrafast Lasers, Mustafa Coskun. “There was nice traffic coming through and it was really nice to connect with colleagues as well as our customers and other visitors. And this is what we're here for: to listen to our customers and understand what their problems are and how we can help them. This Photonics West has been great.”
“This year we were quite busy, even just walking around the show with so many people we know here and so many companies we are in touch with,” said TNO Business Consultant, Optics Manufacturing, Bart Snijders. “It’s great to see them all again. We’ve enjoyed being busy on the floor, busy with meetings. I would always like the show to be six or nine days long, because time is always too short for me here.”
During the Photonics West week, SPIE also announced its latest partnership – this one with The University of Manchester – in the SPIE Endowment Matching Program.
SPIE Photonics West 2025 will take place 25-30 January at the Moscone Center in San Francisco. The call for papers for the 2025 event will open in Spring of 2024.
About SPIE
SPIE, the international society for optics and photonics, brings engineers, scientists, students, and business professionals together to advance light-based science and technology. The Society, founded in 1955, connects and engages with our global constituency through industry-leading conferences and exhibitions; publications of conference proceedings, books, and journals in the SPIE Digital Library; and career-building opportunities. Over the past five years, SPIE has contributed more than $24 million to the international optics community through our advocacy and support, including scholarships, educational resources, travel grants, endowed gifts, and public-policy development. www.spie.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240208158413/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom